cardiovascularКардиоваскулярная терапия и профилактикаCardiovascular Therapy and Prevention1728-88002619-0125«SILICEA-POLIGRAF» LLC10.15829/1728-8800-2021-3139cardiovascular-3139Research ArticleЭНДОВАСКУЛЯРНЫЕ ВМЕШАТЕЛЬСТВАENDOVASCULAR INTERVENTIONSЭффективность радиочастотной денервации почечных артерий при заболеваниях, связанных с повышенной активностью симпатической нервной системыEffectiveness of radiofrequency renal denervation in diseases with increased sympathetic nervous system activityhttps://orcid.org/0000-0003-0346-9069РуденкоБ. А.RudenkoB. A.

Борис Александрович Руденко — доктор медицинских наук, врач рентгенэндоваскулярных методов диагностики и лечения, руководитель отдела инновационных эндоваскулярных методов профилактики и лечения сердечно-сосудистых заболеваний.

Москва. Тел.: +7 (916) 673-27-97

Moscow

brudenko@gnicpm.ruhttps://orcid.org/0000-0003-3851-4544ФещенкоД. А.FeshchenkoD. A.

Дарья Анатольевна Фещенко — младший научный сотрудник отдела инновационных эндоваскулярных методов профилактики и лечения сердечно-сосудистых заболеваний, врач рентгенэндоваскулярных методов диагностики и лечения, зав. операционным блоком.

Москва

Moscow

dasha.feshenko@icloud.comhttps://orcid.org/0000-0003-2602-5006ВасильевД. К.VasilievD. K.

Дмитрий Константинович Васильев — младший научный сотрудник отдела инновационных эндоваскулярных методов профилактики и лечения сердечно-сосудистых заболеваний, врач рентгенэндоваскулярных методов диагностики и лечения.

Москва

Moscow

dfeshenko@gnicpm.ruhttps://orcid.org/0000-0001-7307-1502ШукуровФ. Б.ShukurovF. B.

Фирдавс Баходурович Шукуров — врач рентгенэндоваскулярных методов диагностики и лечения.

Москва

Moscow

dfeshenko@gnicpm.ruhttps://orcid.org/0000-0003-3119-6758ШаноянА. С.ShanoyanA. S.

Артем Сергеевич Шаноян — кандидат медицинских наук, зав. отделением рентгенхирургических методов диагностики и лечения.

Москва

Moscow

dfeshenko@gnicpm.ruhttps://orcid.org/0000-0001-7131-8049МамедовМ. Н.MamedovM. N.

Мехман Ниязович Мамедов — доктор медицинских наук, профессор, руководитель лаборатории прогнозирования и коррекции сердечно-сосудистого риска.

Москва

Moscow

dfeshenko@gnicpm.ruhttps://orcid.org/0000-0002-4453-8430ДрапкинаО. М.DrapkinaO. M.

Оксана Михайловна Драпкина — доктор медицинских наук, профессор, член-корр. РАН, директор.

Москва

Moscow

dfeshenko@gnicpm.ruФГБУ Национальный медицинский исследовательский центр терапии и профилактической медицины Минздрава РоссииNational Medical Research Center for Therapy and Preventive Medicine20210801202220831393139Copyright © Руденко Б.А., Фещенко Д.А., Васильев Д.К., Шукуров Ф.Б., Шаноян А.С., Мамедов М.Н., Драпкина О.М., 20222022Руденко Б.А., Фещенко Д.А., Васильев Д.К., Шукуров Ф.Б., Шаноян А.С., Мамедов М.Н., Драпкина О.М.Rudenko B.A., Feshchenko D.A., Vasiliev D.K., Shukurov F.B., Shanoyan A.S., Mamedov M.N., Drapkina O.M.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://cardiovascular.elpub.ru/jour/article/view/3139

В статье рассмотрена роль гиперактивности симпатической нервной системы в патогенезе различных патологических состояний (артериальная гипертензия, хроническая сердечная недостаточность, фибрилляция предсердий, метаболический синдром, сахарный диабет и системная воспалительная реакция). На примере крупных рандомизированных клинических исследований с использованием катетеров для радиочастотной аблации убедительно доказан антигипертензивный эффект у пациентов c неконтролируемой артериальной гипертензией. Исследования по эффективности метода дали мощный толчок к возможной немедикаментозной коррекции состояний, связанных с повышенной активностью симпатической нервной системы. Проанализированы первые экспериментальные и клинические исследования эффективности ренальной денервации в снижении активности маркеров воспаления, частоты пароксизмов фибрилляции предсердий и желудочковых нарушений ритма сердца, улучшении сократительной способности миокарда левого желудочка. Детально изучены первые клинические результаты положительного воздействия ренальной денервации на показатели углеводного обмена (инсулинорезистентность и уровень гликемии) у пациентов с метаболическим синдром и сахарным диабетом.

The article discusses the role of sympathetic nervous system hyperactivity in the pathogenesis of various pathologies (hypertension, heart failure, atrial fibrillation, metabolic syndrome, diabetes and systemic inflammatory response syndrome). On the example of large randomized clinical trials using catheter-based radiofrequency ablation, the antihypertensive effect in patients with uncontrolled hypertension has been proven. The first experimental and clinical studies on the effectiveness of renal denervation in reducing the activity of inflammatory markers, the incidence of atrial fibrillation and ventricular arrhythmia episodes, and improving the left ventricular contractility. The first clinical results of the favorable effect of renal denervation on carbohydrate metabolism (insulin resistance and glycemic level) in patients with metabolic syndrome and diabetes have been studied in detail.

артериальная гипертензиярадиочастотная аблацияденервация почечных артерийсахарный диабетгипер-симпатикотонияhypertensionradiofrequency ablationrenal denervationdiabetessympathetic hyperactivityReferencesDaugherty SL, Powers JD, Magid DJ, et al. Incidence and prognosis of resistant hypertension in hypertensive patients. Circulation. 2012; 125( 13): 1635-42. doi:10.1161/CIRCULATIONAHA.111.068064.Daugherty SL, Powers JD, Magid DJ, et al. Incidence and prognosis of resistant hypertension in hypertensive patients. Circulation. 2012; 125( 13): 1635-42. doi:10.1161/CIRCULATIONAHA.111.068064.Kearney PM, Whelton M, Reynolds K, et al. Global burden of hypertension: analysis of worldwide data. Lancet. 2005;365(9455):217-23. doi:10.1016/S0140-6736(05)17741-1.Kearney PM, Whelton M, Reynolds K, et al. Global burden of hypertension: analysis of worldwide data. Lancet. 2005;365(9455):217-23. doi:10.1016/S0140-6736(05)17741-1.Osborn JW, Foss JD. Renal Nerves and Long-Term Control of Arterial Pressure. Compr Physiol. 2017;7(2):263-320. doi:10.1002/cphy.c150047.Osborn JW, Foss JD. Renal Nerves and Long-Term Control of Arterial Pressure. Compr Physiol. 2017;7(2):263-320. doi:10.1002/cphy.c150047.Muller J, Barajas L. Electron microscopic and histochemical evidence for a tubular innervation in the renal cortex of the monkey. J Ultrastruct Res. 1972;41(5):533-49. doi: 10.1016/s0022-5320(72)90054-8.Muller J, Barajas L. Electron microscopic and histochemical evidence for a tubular innervation in the renal cortex of the monkey. J Ultrastruct Res. 1972;41(5):533-49. doi: 10.1016/s0022-5320(72)90054-8.Delacroix S, Chokka RG, Worthley SG. Hypertension: Pathophysiology and Treatment. J Neurol Neurophysiol. 2014;5:6. doi:10.4172/2155-9562.1000250.Delacroix S, Chokka RG, Worthley SG. Hypertension: Pathophysiology and Treatment. J Neurol Neurophysiol. 2014;5:6. doi:10.4172/2155-9562.1000250.Grimson KS, Orgain ES, Anderson B, et al. Total thoracic and partial to total lumbar sympathectomy, splanchnicectomy and celiac ganglionectomy for hypertension. Ann Surg. 1953;138(4):532-47. doi:10.1097/00000658-195310000-00006.Grimson KS, Orgain ES, Anderson B, et al. Total thoracic and partial to total lumbar sympathectomy, splanchnicectomy and celiac ganglionectomy for hypertension. Ann Surg. 1953;138(4):532-47. doi:10.1097/00000658-195310000-00006.Schlaich MP, Sobotka PA, Krum H, et al. Renal sympathetic-nerve ablation for uncontrolled hypertension. N Engl J Med. 2009;361(9):932-4. doi:10.1056/NEJMc0904179.Schlaich MP, Sobotka PA, Krum H, et al. Renal sympathetic-nerve ablation for uncontrolled hypertension. N Engl J Med. 2009;361(9):932-4. doi:10.1056/NEJMc0904179.Krum H, Schlaich M, Whitbourn R, et al. Catheter-based renal sympathetic denervation for resistant hypertension: a multicenter safety and proof-of-principle cohort study. Lancet 2009;373(9671):1275-81. doi:10.1016/S0140-6736(09)60566-3.Krum H, Schlaich M, Whitbourn R, et al. Catheter-based renal sympathetic denervation for resistant hypertension: a multicenter safety and proof-of-principle cohort study. Lancet 2009;373(9671):1275-81. doi:10.1016/S0140-6736(09)60566-3.Krum H, Schlaich MP, Sobotka PA, et al. Percutaneous renal denervation in patients with treatment-resistant hypertension: final 3-year report of the Symplicity HTN-1 study [published correction appears in Lancet. 2014;383(9917):602. Sobotka, Paul A [added]]. Lancet. 2014;383(9917):622-9. doi:10.1016/S0140-6736(13)62192-3.Krum H, Schlaich MP, Sobotka PA, et al. Percutaneous renal denervation in patients with treatment-resistant hypertension: final 3-year report of the Symplicity HTN-1 study [published correction appears in Lancet. 2014;383(9917):602. Sobotka, Paul A [added]]. Lancet. 2014;383(9917):622-9. doi:10.1016/S0140-6736(13)62192-3.Esler MD, Krum H, Schlaich M, et al. Renal sympathetic denervation for treatment of drug-resistant hypertension: one-year results from the Symplicity HTN-2 randomized, controlled trial. Circulation. 2012;126(25):2976-82. doi:10.1161/CIRCULATIONAHA.112.130880.Esler MD, Krum H, Schlaich M, et al. Renal sympathetic denervation for treatment of drug-resistant hypertension: one-year results from the Symplicity HTN-2 randomized, controlled trial. Circulation. 2012;126(25):2976-82. doi:10.1161/CIRCULATIONAHA.112.130880.Bhatt DL, Kandzari DE, O’Neill WW, et al. A controlled trial of renal denervation for resistant hypertension. N Engl J Med. 2014;370(15):1393-1401. doi:10.1056/NEJMoa1402670.Bhatt DL, Kandzari DE, O’Neill WW, et al. A controlled trial of renal denervation for resistant hypertension. N Engl J Med. 2014;370(15):1393-1401. doi:10.1056/NEJMoa1402670.Sakakura K, Ladich E, Cheng Q, et al. Anatomic assessment of sympathetic peri-arterial renal nerves in man. J Am Coll Cardiol. 2014;64(7):635-43. doi:10.1016/j.jacc.2014.03.059.Sakakura K, Ladich E, Cheng Q, et al. Anatomic assessment of sympathetic peri-arterial renal nerves in man. J Am Coll Cardiol. 2014;64(7):635-43. doi:10.1016/j.jacc.2014.03.059.Mompeo B, Maranillo E, Garcia-Touchard A, et al. The gross anatomy of the renal sympathetic nerves revisited. Clin Anat. 2016;29(5):660-4. doi:10.1002/ca.22720.Mompeo B, Maranillo E, Garcia-Touchard A, et al. The gross anatomy of the renal sympathetic nerves revisited. Clin Anat. 2016;29(5):660-4. doi:10.1002/ca.22720.Mahfoud F, Edelman ER, Bohm M. Catheter-based renal denervation is no simple matter: lessons to be learned from our anatomy? J Am Coll Cardiol. 2014;64(7):644-6. doi: 10.1016/j.jacc.2014.05.037Mahfoud F, Edelman ER, Bohm M. Catheter-based renal denervation is no simple matter: lessons to be learned from our anatomy? J Am Coll Cardiol. 2014;64(7):644-6. doi: 10.1016/j.jacc.2014.05.037Kandzari DE, Bohm M, Mahfoud F, et al. Effect of renal denervation on blood pressure in the presence of antihypertensive drugs: 6-month efficacy and safety results from the SPYRAL HTN-ON MED proof-of-concept randomized trial. Lancet. 2018;391(10137):2346-55. doi:10.1016/S0140-6736(18)30951-6.Kandzari DE, Bohm M, Mahfoud F, et al. Effect of renal denervation on blood pressure in the presence of antihypertensive drugs: 6-month efficacy and safety results from the SPYRAL HTN-ON MED proof-of-concept randomized trial. Lancet. 2018;391(10137):2346-55. doi:10.1016/S0140-6736(18)30951-6.Bohm M, Kario K, Kandzari DE, et al. Efficacy of catheter-based renal denervation in the absence of antihypertensive medications (SPYRAL HTN-OFF MED Pivotal): a multicentre, randomised, sham-controlled trial. Lancet. 2020;395(10234):1444-51. doi:10.1016/S0140-6736(20)30554-7.Bohm M, Kario K, Kandzari DE, et al. Efficacy of catheter-based renal denervation in the absence of antihypertensive medications (SPYRAL HTN-OFF MED Pivotal): a multicentre, randomised, sham-controlled trial. Lancet. 2020;395(10234):1444-51. doi:10.1016/S0140-6736(20)30554-7.Gao JQ, Yang W, Liu ZJ. Percutaneous renal artery denervation in patients with chronic systolic heart failure: A randomized controlled trial. Cardiol J. 2019;26(5):503-10. doi:10.5603/CJ.a2018.0028.Gao JQ, Yang W, Liu ZJ. Percutaneous renal artery denervation in patients with chronic systolic heart failure: A randomized controlled trial. Cardiol J. 2019;26(5):503-10. doi:10.5603/CJ.a2018.0028.Pokushalov E, Romanov A, Corbucci G, et al. A randomized comparison of pulmonary vein isolation with versus without concomitant renal artery denervation in patients with refractory symptomatic atrial fibrillation and resistant hypertension. J Am Coll Cardiol. 2012;60(13): 1163-70. doi: 10.1016/j.jacc.2012.05.036.Pokushalov E, Romanov A, Corbucci G, et al. A randomized comparison of pulmonary vein isolation with versus without concomitant renal artery denervation in patients with refractory symptomatic atrial fibrillation and resistant hypertension. J Am Coll Cardiol. 2012;60(13): 1163-70. doi: 10.1016/j.jacc.2012.05.036.Tsioufis KP, Tsiachris V, Dimitriadis D, et al. Renal sympathetic denervation significantly reduces mean heart rate and exerts a favorable effect on atrial and ventricular arrhythmias in resistant hypertesives. J Am Coll Cardiol. 2013;61:10:E1376. doi: 10.1016/S0735-1097(13)61376-5.Tsioufis KP, Tsiachris V, Dimitriadis D, et al. Renal sympathetic denervation significantly reduces mean heart rate and exerts a favorable effect on atrial and ventricular arrhythmias in resistant hypertesives. J Am Coll Cardiol. 2013;61:10:E1376. doi: 10.1016/S0735-1097(13)61376-5.Witkowski A, Prejbisz A, Florczak E, et al. Effects of renal sympathetic denervation on blood pressure, sleep apnea course, and glycemic control in patients with resistant hypertension and sleep apnea. Hypertension. 2011;58(4):559-65. doi: 10.1161/HYPERTENSIONAHA.111.173799.Witkowski A, Prejbisz A, Florczak E, et al. Effects of renal sympathetic denervation on blood pressure, sleep apnea course, and glycemic control in patients with resistant hypertension and sleep apnea. Hypertension. 2011;58(4):559-65. doi: 10.1161/HYPERTENSIONAHA.111.173799.Flaa A, Aksnes TA, Kjeldsen SE, et al. Increased sympathetic reactivity may predict insulin resistance: an 18-year followup study. Metabolism. 2008;57(10):1422-7 doi: 10.1016/j.metabol.2008.05.012.Flaa A, Aksnes TA, Kjeldsen SE, et al. Increased sympathetic reactivity may predict insulin resistance: an 18-year followup study. Metabolism. 2008;57(10):1422-7 doi: 10.1016/j.metabol.2008.05.012.Masuo K, Mikami H, Ogihara T, Tuck ML. Sympathetic nerve hyperactivity precedes hyperinsulinemia and blood pressure elevation in a young, nonobese Japanese population. Am J Hypertens. 1997; 10(1 ):77-83. doi:10.1016/s0895-7061(96)00303-2.Masuo K, Mikami H, Ogihara T, Tuck ML. Sympathetic nerve hyperactivity precedes hyperinsulinemia and blood pressure elevation in a young, nonobese Japanese population. Am J Hypertens. 1997; 10(1 ):77-83. doi:10.1016/s0895-7061(96)00303-2.Whiting DR, Guariguata L, Weil C, Shaw J. IDF diabetes atlas: global estimates of the prevalence of diabetes for 2011 and 2030. Diabetes Res Clin Pract. 2011;94(3):311-21. doi:10.1016/j.diabres.2011.10.029.Whiting DR, Guariguata L, Weil C, Shaw J. IDF diabetes atlas: global estimates of the prevalence of diabetes for 2011 and 2030. Diabetes Res Clin Pract. 2011;94(3):311-21. doi:10.1016/j.diabres.2011.10.029.Kahn SE, Cooper ME, Del Prato S. Pathophysiology and treatment of type 2 diabetes: perspectives on the past, present, and future. Lancet. 2014;383(9922):1068-83. doi: 10.1016/S0140-6736(13)62154-6.Kahn SE, Cooper ME, Del Prato S. Pathophysiology and treatment of type 2 diabetes: perspectives on the past, present, and future. Lancet. 2014;383(9922):1068-83. doi: 10.1016/S0140-6736(13)62154-6.Huggett RJ, Scott EM, Gilbey SG, et al. Impact of type 2 diabetes mellitus on sympathetic neural mechanisms in hypertension. Circulation. 2003;108(25):3097-101. doi: 10.1161/01.CIR.0000103123.66264.FE.Huggett RJ, Scott EM, Gilbey SG, et al. Impact of type 2 diabetes mellitus on sympathetic neural mechanisms in hypertension. Circulation. 2003;108(25):3097-101. doi: 10.1161/01.CIR.0000103123.66264.FE.Santulli G, Lombardi A, Sorriento D, et al. Age-related impairment in insulin release: the essential role of P(2)-adrenergic receptor. Diabetes. 2012;61(3):692-701. doi:10.2337/db11-1027Santulli G, Lombardi A, Sorriento D, et al. Age-related impairment in insulin release: the essential role of P(2)-adrenergic receptor. Diabetes. 2012;61(3):692-701. doi:10.2337/db11-1027Iyer MS, Bergman RN, Korman JE, et al. Renal Denervation Reverses Hepatic Insulin Resistance Induced by High-Fat Diet. Diabetes. 2016;65(11):3453-63. doi:10.2337/db16-0698.Iyer MS, Bergman RN, Korman JE, et al. Renal Denervation Reverses Hepatic Insulin Resistance Induced by High-Fat Diet. Diabetes. 2016;65(11):3453-63. doi:10.2337/db16-0698.Pan T, Guo JH, Ling L, et al. Effects of Multi-Electrode Renal Denervation on Insulin Sensitivity and Glucose Metabolism in a Canine Model of Type 2 Diabetes Mellitus. J Vasc Interv Radiol. 2018;29(5):731-8.e2. doi:10.1016/j.jvir.201712.011.Pan T, Guo JH, Ling L, et al. Effects of Multi-Electrode Renal Denervation on Insulin Sensitivity and Glucose Metabolism in a Canine Model of Type 2 Diabetes Mellitus. J Vasc Interv Radiol. 2018;29(5):731-8.e2. doi:10.1016/j.jvir.201712.011.Wang Y, Rijal B, Xu M, et al. Renal denervation improves vascular endothelial dysfunction by inducing autophagy via AMPK/mTOR signaling activation in a rat model of type 2 diabetes mellitus with insulin resistance. Acta Diabetol. 2020;57(10):1227-43. doi:10.1007/s00592-020-01532-6.Wang Y, Rijal B, Xu M, et al. Renal denervation improves vascular endothelial dysfunction by inducing autophagy via AMPK/mTOR signaling activation in a rat model of type 2 diabetes mellitus with insulin resistance. Acta Diabetol. 2020;57(10):1227-43. doi:10.1007/s00592-020-01532-6.Liu HY, Han J, Cao SY, et al. Hepatic autophagy is suppressed in the presence of insulin resistance and hyperinsulinemia: inhibition of FoxO1-dependent expression of key autophagy genes by insulin. J Biol Chem. 2009;284(45):31484-92. doi:10.1074/jbc.M109.033936.Liu HY, Han J, Cao SY, et al. Hepatic autophagy is suppressed in the presence of insulin resistance and hyperinsulinemia: inhibition of FoxO1-dependent expression of key autophagy genes by insulin. J Biol Chem. 2009;284(45):31484-92. doi:10.1074/jbc.M109.033936.Chatterjee T, Pattanayak R, Ukil A, et al. Autophagy protects peripheral blood mononuclear cells against inflammation, oxidative and nitrosative stress in diabetic dyslipidemia. Free Radic Biol Med. 2019;143:309-23. doi: 10.1016/j.freeradbiomed.2019.07.034.Chatterjee T, Pattanayak R, Ukil A, et al. Autophagy protects peripheral blood mononuclear cells against inflammation, oxidative and nitrosative stress in diabetic dyslipidemia. Free Radic Biol Med. 2019;143:309-23. doi: 10.1016/j.freeradbiomed.2019.07.034.Mahfoud F, Cremers B, Janker J, et al. Renal hemodynamics and renal function after catheter-based renal sympathetic denervation in patients with resistant hypertension. Hypertension. 2012;60(2):419-24. doi:10.1161/HYPERTENSIONAHA.112.193870.Mahfoud F, Cremers B, Janker J, et al. Renal hemodynamics and renal function after catheter-based renal sympathetic denervation in patients with resistant hypertension. Hypertension. 2012;60(2):419-24. doi:10.1161/HYPERTENSIONAHA.112.193870.Verloop WL, Spiering W, Vink EE, et al. Denervation of the renal arteries in metabolic syndrome: the DREAMS-study. Hypertension. 2015;65(4):751-7 doi: 10.1161/HYPERTENSIONAHA.114.04798.Verloop WL, Spiering W, Vink EE, et al. Denervation of the renal arteries in metabolic syndrome: the DREAMS-study. Hypertension. 2015;65(4):751-7 doi: 10.1161/HYPERTENSIONAHA.114.04798.

The authors declare that there are no conflicts of interest present.